PROTEOME SCIENCES PLC PROTEOME SCIENCES PRESENTING ON BLOOD BIOMARKERS AND TAU TARGETED THERAPIES AT GLOBAL ALZHEIMER'S DISEASE CONFERENCE, AD/PD 2015.
Cobham, UK, March 18th2015: Proteome Sciences plc, a global leader in proteomics, is pleased to announce that it will present four posters at the 12thInternational Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders which opens today in Nice, France. The posters highlight recent developments in Proteome Sciences' proprietary biomarker discovery
technologies for enhanced biomarker discovery, mapping of cell signaling pathways and targeted
mass spectrometry methods for a blood biomarker of Alzheimer's disease.
Application of SysQuant®to map cell signaling and regulatory pathway changes in response to
kinase inhibitor treatment.
Demonstration of a targeted method for measurement of clusterin isoforms that predict Alzheimer's disease severity/progression
Poster #295 (Friday March 20th) - Casein kinase 1 inhibitors beneficially modulate tau phosphorylation and cell signaling pathways in a transgenic model of human tauopathyMultiple pathway changes occurring in a phospho-‐tau dose-‐dependent manner in human Alzheimer's disease are reversed by orally available Casein Kinase 1d inhibitors
Poster #070 (Saturday March 21st) - TMTcalibrator+reveals biomarkers of microglial activation in AD CSF
Novel strategy for identifying low-‐abundant disease-‐relevant biomarkers delivers early signals
of neuroinflammation in Alzheimer's disease cerebrospinal fluid
Dr. Ian Pike, Chief Operating Officer of Proteome Sciences, who will be attending the conference,
commented:
"We are delighted that four different aspects of our proteomics research in Alzheimer's disease have been selected for presentation in Nice. The AD/PD conference is an important venue for dissemination of the latest biomarker and drug development research and presents us with a great opportunity to showcase our expertise to potential partners and clients.
"We have made very significant contributions to improving the way we can discover and validate disease-‐relevant biomarkers that have the potential to rapidly translate from discovery into diagnostic assay development. Our CK1d inhibitor program has also progressed strongly and the use of SysQuant® has allowed us to demonstrate that many of
the pathways affected by worsening tau pathology in human disease are reversed in a rodent model treated with PS110 and PS278-‐05, our two lead inhibitors."
More details will be available at www.proteomics.com
Christopher Pearce, Executive Chairman
Dr. Ian Pike, Chief Operating Officer Tel: +44 (0)1932 865065
Geoff Ellis, Finance Director
Mark Connelly/Callum Davidson
finnCap
Geoff Nash
Tel: +44 (0)20 7397 8900
Tel : +44 (0)20 7220 0563
Adrian Shaw Tel: +44 (0)1483 271291
Mobile +44(0)7979 900733
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.
Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.
The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.
|
distributed by
|
